BanderasNews
Puerto Vallarta Weather Report
Welcome to Puerto Vallarta's liveliest website!
Contact UsSearch
Why Vallarta?Vallarta WeddingsRestaurantsWeatherPhoto GalleriesToday's EventsMaps
 NEWS/HOME
 EDITORIALS
 ENTERTAINMENT
 VALLARTA LIVING
 PV REAL ESTATE
 TRAVEL / OUTDOORS
 HEALTH / BEAUTY
 SALON & SPA SERVICES
 HEALTH FOR WOMEN
 HEALTH FOR MEN
 YOUR WELL BEING
 THE CHALLENGE CORNER
 DENTAL HEALTH
 ON ADDICTION
 RESOURCES
 SPORTS
 DAZED & CONFUSED
 PHOTOGRAPHY
 CLASSIFIEDS
 READERS CORNER
 BANDERAS NEWS TEAM
Sign up NOW!

Free Newsletter!

Puerto Vallarta News NetworkHealth & Beauty | October 2009 

Obesity Drugs Lumber Toward US Marketplace
email this pageprint this pageemail usShari Roan - Los Angeles Times
go to original
October 30, 2009



(M. Wahl/Tribune Media Services)
About this time last year, we were reporting on the failure of several investigational weight-loss medications. They included Sanofi-Aventis' rimonabant as well as two other drugs that aimed to work by blocking cannabinoid receptors in the brain.

However, one or more new weight-loss drugs may become available next year, based on research presented this week at the Obesity Society's annual meeting in Washington, D.C. Xenical was the last prescription weight-loss medication approved by the Food and Drug Administration, in 1999.

An update on the three leading candidates for approval:

Lorcaserin, made by Arena Pharmaceuticals, reported Phase 3 study results of 4,008 patients who took the medication for one year. Almost half of the patients lost 5% or more of their body weight, and 22.6% lost 10%.

Qnexa, made by Vivus Inc., is a combination of two drugs: phentermine and topiramate. In two Phase 3 studies of 3,750 patients, the average weight loss was 14.7% of body weight (37 pounds) after 56 weeks.

Contrave, made by Orexigen Therapeutics Inc., is also a combination of two medications: buproprion SR and naltrexone SR. In a Phase 3 study, one-third of patients lost 10% of body weight.

The manufacturers all reported acceptable safety profiles, but the FDA will be looking closely at that issue. Rimonabant reached late-stage clinical trials before being abandoned because patients reported an increase in depression symptoms and suicidal thoughts.

"Safety is of paramount importance in treating patients who are overweight or have obesity," Dr. Lee Kaplan, an associate professor of medicine at Harvard who presented the data on lorcaserin, said in a news release. "We need new therapies that help patients reduce their weight and improve cardiovascular factors such as high blood pressure and cholesterol, while avoiding cardiac toxicity and symptoms of depression."



In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving
the included information for research and educational purposes • m3 © 2009 BanderasNews ® all rights reserved • carpe aestus